Evogene Prices Its Initial Public Offering in the United States

  Evogene Prices Its Initial Public Offering in the United States

  - The offering of 5 million ordinary shares prices at US$14.75 per share -

Business Wire

REHOVOT, Israel -- November 20, 2013

Evogene Ltd. (TASE: EVGN) today announced the pricing of its initial public
offering in the U.S. of 5 million ordinary shares at a price of US$14.75 per
share. In connection with the offering, Evogene has granted the underwriters a
30-day option to purchase up to 750,000 additional ordinary shares at the same
price per share.

As part of the offering, one of the company’s shareholders, Monsanto Company,
has agreed to purchase 813,560 ordinary shares at the initial public offering
price, amounting to approximately US$12 million.

The shares are expected to begin trading on the New York Stock Exchange under
the symbol “EVGN” on November 21, 2013. The offering is expected to close on
November 26, 2013.

Credit Suisse Securities and Deutsche Bank Securities are acting as joint
book-running managers for the offering, and Oppenheimer & Co. and Piper
Jaffray & Co. are acting as co-managers.

This offering is being made solely by means of a prospectus, copies of which
may be obtained by contacting: Credit Suisse Securities (USA) LLC, Attention:
Prospectus Department, One Madison Avenue, New York, NY, 10010, telephone: +1
(800) 221-1037, e-mail: newyork.prospectus@credit-suisse.com; or Deutsche Bank
Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY
10005-2836, telephone: +1 (800) 503-4611, email: prospectus.CPDG@db.com.

A registration statement relating to the initial public offering has been
filed with and declared effective by the United States Securities and Exchange
Commission. This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.

About Evogene Ltd.

Evogene is a plant genomics company, utilizing a proprietary integrated
technology infrastructure to enhance seed traits underlying crop productivity.
Evogene offers a complete solution for crop productivity improvement through
biotechnology and advanced breeding using a unique technology infrastructure
that is based on a deep scientific understanding of plant genomics and
proprietary computational capabilities. The Company has strategic
collaborations with world-leading agricultural companies to develop improved
seed traits in relation to yield and a-biotic stress (such as tolerance to
drought), and biotic stress (such as resistance to disease), in key crops as
corn, soybean, wheat and rice. In addition, Evogene has earlier stage
operations in agriculture chemicals and seeds for second generation feedstock
for biodiesel. Evogene’s headquarters are located in Rehovot, Israel and the
Company is listed for trading on the Tel Aviv Stock Exchange (TASE: EVGN).

Contact:

Evogene
Karen Mazor
Director, Public and Investor Relations
T: +972 54 22 88 039
karen.mazor@evogene.com
 
Press spacebar to pause and continue. Press esc to stop.